DK1185299T3 - Anvendelse af antistoffer mod CD20 til behandling af graft versus host disease - Google Patents

Anvendelse af antistoffer mod CD20 til behandling af graft versus host disease

Info

Publication number
DK1185299T3
DK1185299T3 DK00940332T DK00940332T DK1185299T3 DK 1185299 T3 DK1185299 T3 DK 1185299T3 DK 00940332 T DK00940332 T DK 00940332T DK 00940332 T DK00940332 T DK 00940332T DK 1185299 T3 DK1185299 T3 DK 1185299T3
Authority
DK
Denmark
Prior art keywords
treatment
antibodies against
host disease
versus host
graft versus
Prior art date
Application number
DK00940332T
Other languages
Danish (da)
English (en)
Inventor
Andrea Biondi
Josee Golay
Martino Introna
Rambaldi
Original Assignee
Consiglio Nazionale Ricerche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consiglio Nazionale Ricerche filed Critical Consiglio Nazionale Ricerche
Application granted granted Critical
Publication of DK1185299T3 publication Critical patent/DK1185299T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
DK00940332T 1999-06-11 2000-06-07 Anvendelse af antistoffer mod CD20 til behandling af graft versus host disease DK1185299T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT1999MI001299A ITMI991299A1 (it) 1999-06-11 1999-06-11 Uso di anticorpi contro antigeni di superficie per il trattamento della malattia trapianto contro ospite
PCT/EP2000/005212 WO2000076542A1 (en) 1999-06-11 2000-06-07 Use of antibodies against cd20 for the treatment of the graft versus host disease

Publications (1)

Publication Number Publication Date
DK1185299T3 true DK1185299T3 (da) 2007-05-21

Family

ID=11383150

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00940332T DK1185299T3 (da) 1999-06-11 2000-06-07 Anvendelse af antistoffer mod CD20 til behandling af graft versus host disease

Country Status (26)

Country Link
US (1) US20070014785A1 (es)
EP (1) EP1185299B1 (es)
JP (1) JP2003501482A (es)
KR (1) KR20020026455A (es)
CN (1) CN1253208C (es)
AU (1) AU774206B2 (es)
BG (1) BG106193A (es)
CA (1) CA2376288A1 (es)
CZ (1) CZ20014450A3 (es)
DE (1) DE60033030T2 (es)
DK (1) DK1185299T3 (es)
EE (1) EE200100667A (es)
ES (1) ES2278616T3 (es)
HK (1) HK1043549B (es)
HU (1) HUP0201600A3 (es)
IL (1) IL146934A0 (es)
IS (1) IS6195A (es)
IT (1) ITMI991299A1 (es)
NO (1) NO20016035L (es)
NZ (1) NZ515992A (es)
PL (1) PL352860A1 (es)
PT (1) PT1185299E (es)
SK (1) SK18132001A3 (es)
TR (1) TR200103581T2 (es)
WO (1) WO2000076542A1 (es)
ZA (1) ZA200110004B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU777970C (en) 1999-05-07 2006-08-17 F. Hoffman-La Roche Ag Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
SI1572744T1 (sl) * 2002-12-16 2010-09-30 Genentech Inc Imunoglobulinske variante in njihove uporabe
CN1316019C (zh) * 2002-12-26 2007-05-16 中国医学科学院中国协和医科大学血液学研究所血液病医院 抗cd20嵌合抗体突变体基因及其应用
US20040202658A1 (en) 2003-04-09 2004-10-14 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to TNF-alpha inhibitor
AU2004252067B2 (en) 2003-05-09 2012-04-12 Duke University CD20-specific antibodies and methods of employing same
JP2007526220A (ja) 2003-06-05 2007-09-13 ジェネンテック・インコーポレーテッド Ｂ細胞疾患の併用療法
CA2560751A1 (en) * 2004-03-22 2005-10-06 The Ohio State University Research Foundation Methods for transfecting natural killer cells
AR049200A1 (es) 2004-06-04 2006-07-05 Genentech Inc Metodo para tratar esclerosis multiple con una composicion que contiene un anticuerpo cd20
CN101001873B (zh) 2004-08-04 2013-03-13 曼璀克生物科技有限责任公司 Fc区变体
KR20080046135A (ko) 2005-05-20 2008-05-26 제넨테크, 인크. 자가면역 질환 대상체로부터의 생물학적 샘플의 예비처리
ES2460517T3 (es) 2005-07-25 2014-05-13 Emergent Product Development Seattle, Llc Reducción de células b mediante el uso de moléculas de unión específica a cd37 y de unión específica a cd20
AU2006272597A1 (en) 2005-07-25 2007-02-01 Emergent Product Development Seattle Llc Single dose use of CD20-specific binding molecules
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
JP6088723B2 (ja) 2005-11-23 2017-03-01 ジェネンテック， インコーポレイテッド Ｂ細胞アッセイに関する組成物及び方法。
CN101008291B (zh) * 2006-01-26 2010-05-12 金海产品有限公司 用于水池清洁机的密封盒装置
KR101571027B1 (ko) 2006-06-12 2015-11-23 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 효과기 기능을 갖는 단일쇄 다가 결합 단백질
CA2584494A1 (en) * 2007-03-27 2008-09-27 Jeffrey A. Medin Vector encoding therapeutic polypeptide and safety elements to clear transduced cells
KR101432191B1 (ko) * 2007-06-22 2014-08-20 훗카이도 코리츠 다이가쿠 호진 삿포르 이카 다이가쿠 이식편대숙주 질환의 검출 또는 치료 방법
LT3597659T (lt) 2007-07-09 2023-05-10 Genentech, Inc. Disulfidinės jungties redukcijos prevencijos būdas gaminant polipeptidą rekombinantiniu būdu
ES2527297T3 (es) 2007-07-31 2015-01-22 Regeneron Pharmaceuticals, Inc. Anticuerpos humanos para CD20 humano y método para utilizar los mismos
EP2200631A1 (en) 2007-10-16 2010-06-30 Zymogenetics, Inc. Combination of blys inhibition and anti-cd 20 agents for treatment of autoimmune disease
EP2077281A1 (en) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
US8568709B2 (en) 2008-03-20 2013-10-29 University Health Network Thymidylate kinase fusions and uses thereof
CN102099377A (zh) 2008-04-11 2011-06-15 新兴产品开发西雅图有限公司 Cd37免疫治疗剂及其与双功能化学治疗剂的联合
AR073295A1 (es) 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
PT2464725T (pt) 2009-08-11 2020-05-21 Hoffmann La Roche Produção de proteínas em meios de cultura celular isentos de glutamina
MX341687B (es) 2010-02-10 2016-08-30 Immunogen Inc "anticuerpos cd20 y su utilización".
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
DK3221359T3 (da) 2014-11-17 2020-06-22 Regeneron Pharma Fremgangsmåder til tumorbehandling ved anvendelse af CD3XCD20-bispecifikt antistof
EP3660035A1 (en) 2015-05-30 2020-06-03 Molecular Templates, Inc. De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
BR112017024610A2 (pt) 2015-06-24 2018-07-31 F. Hoffmann-La Roche Ag anticorpos para receptor antitransferrina com afinidade especificada
CA2999138C (en) 2015-09-21 2024-05-21 Aptevo Research And Development Llc Cd3 binding polypeptides
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
RU2753390C1 (ru) 2015-10-02 2021-08-13 Ф. Хоффманн-Ля Рош Аг Биспецифические антитела к человеческому cd20/человеческому рецептору трансферрина и способы их применения
US20180206726A1 (en) 2016-12-07 2018-07-26 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
EP3600416B1 (en) 2017-03-30 2023-06-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
US20230009902A1 (en) 2018-06-20 2023-01-12 Progenity, Inc. Treatment of a disease or condition in a tissue orginating from the endoderm
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
AU2019331024A1 (en) 2018-08-31 2021-03-18 Regeneron Pharmaceuticals, Inc. Dosing strategy that mitigates cytokine release syndrome for CD3/C20 bispecific antibodies
WO2020106754A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272082A (en) * 1992-03-30 1993-12-21 The Wistar Institute Of Anatomy & Biology Cytotoxic T-ALL cell lines and uses therefor
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
EP0977595A4 (en) * 1996-05-31 2001-05-16 Genetic Therapy Inc PREVENTION OF GAS REACTION AGAINST HOST USING THYMO-DEPENDENT LYMPHOCYTES CONTAINING POLYNUCLEOTIDES ENCODING NEGATIVE SELECTION MARKERS
GB9705744D0 (en) * 1997-03-20 1997-05-07 Davies Alison M Methods for selecting cells and their uses

Also Published As

Publication number Publication date
CA2376288A1 (en) 2000-12-21
NO20016035D0 (no) 2001-12-10
PL352860A1 (en) 2003-09-08
EP1185299A1 (en) 2002-03-13
AU5530300A (en) 2001-01-02
US20070014785A1 (en) 2007-01-18
BG106193A (bg) 2002-08-30
TR200103581T2 (tr) 2002-08-21
CN1355712A (zh) 2002-06-26
WO2000076542A1 (en) 2000-12-21
SK18132001A3 (sk) 2002-05-09
IL146934A0 (en) 2002-08-14
CZ20014450A3 (cs) 2002-04-17
ES2278616T3 (es) 2007-08-16
HUP0201600A3 (en) 2005-04-28
HK1043549A1 (en) 2002-09-20
KR20020026455A (ko) 2002-04-10
IS6195A (is) 2001-12-10
ITMI991299A1 (it) 2000-12-11
AU774206B2 (en) 2004-06-17
JP2003501482A (ja) 2003-01-14
ZA200110004B (en) 2003-02-26
HUP0201600A2 (en) 2002-08-28
DE60033030T2 (de) 2007-05-31
NO20016035L (no) 2002-02-11
EE200100667A (et) 2003-02-17
HK1043549B (zh) 2006-09-01
DE60033030D1 (de) 2007-03-08
EP1185299B1 (en) 2007-01-17
PT1185299E (pt) 2007-03-30
NZ515992A (en) 2004-01-30
CN1253208C (zh) 2006-04-26
ITMI991299A0 (it) 1999-06-11

Similar Documents

Publication Publication Date Title
DK1185299T3 (da) Anvendelse af antistoffer mod CD20 til behandling af graft versus host disease
EE200300239A (et) Rosuvastatiini (ZD4522) kasutamine heterosügootseperekondliku hüperkolesteroleemia raviks
EE200000470A (et) Inimese CD40-vastased antikehad
BR0001826B1 (pt) fralda descartÁvel.
DK1292594T3 (da) Quinazolinderivater til behandling af tumorer
BR0106049B1 (pt) fralda descartÁvel.
DK1196172T3 (da) (S,S)-reboxetin til behandling af kronisk smerte
DK1259512T3 (da) Pteridinforbindelser til behandling af psoreasis
IT1315260B1 (it) Bendaggio gastrico rimovibile
DK1144395T3 (da) 2-amino-benzoxazinon-derivater til behandling af fedme
AR027976A1 (es) Anticuerpos humanos para cd154
EE200300179A (et) Humaniseeritud LT-ß-R-i vastased antikehad
EP1575491A4 (en) TREATMENT OF RENAL CARCINOMA USING ANTIBODIES AGAINST THE EPIDERMAL GROWTH FACTOR RECEPTOR
DK1282616T3 (da) Hydroxyphenylpiperidin-4-ylidenmethylbenzamidderivater til behandling af smerter
BR0103960B1 (pt) fralda descartável.
DK1176964T3 (da) Brug af ET743 til behandling af cancer
NO20023482D0 (no) Fremgangsmåte for behandling av stoffmisbruk
BR0000706B1 (pt) fralda descartÁvel.
BR0001216B1 (pt) fralda descartÁvel.
BR0104760B1 (pt) fralda descartável.
ES1048994Y (es) Nido desechable para cunicultura.
NO20026219L (no) Forbindelser for behandling av svekket fundisk relaksasjon
DK1229936T3 (da) Anvendelse af anti-idiotypiske antistoffer som vacciner mod cancer
DK1350521T3 (da) Immunoterapeutiske kombinationer til behandling af tumorer
BR0004412B1 (pt) fralda descartÁvel.